Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

RELMADA THERAPEUTICS, INC. (RLMD)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsJun-30-23Mar-31-23Sep-30-22Jun-30-22Mar-31-22Sep-30-21Jun-30-21Mar-31-21
   10-Q10-Q10-Q10-Q10-Q10-Q10-Q10-Q
Operating expenses:          
Research and development  13.715.930.530.9 34.017.314.0
General and administrative  12.312.38.214.6 8.79.18.4
    Total operating expenses  26.028.238.797.4 42.726.522.4
    Loss from operations  -26.0-28.2-38.7-45.5 -42.7-26.5-22.4
   
Other (expenses) income:          
Gain on settlement of fees     6.4    
Interest/investment income, net  1.42.50.80.4 0.30.30.4
Realized (loss) gain on short-term investments   -0.7-0.60.0 -0.3-0.1-0.1
   
Unrealized (loss) gain on short-term investments          
    Total other income  0.71.8-0.75.6 0.0-0.10.2
    Net loss  -25.3-26.3-39.4-39.9-39.7-42.6-26.6-22.2
   
Loss per common share – basic (in Dollars per share)  ($0.84)($0.87)($1.31)($1.33) ($2.44)($1.56)($1.34)
   
Weighted average number of common shares outstanding – basic (in Shares)  30.130.130.129.928.417.517.116.6

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy